TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33981732

Group type: EXPERIMENTAL
Intervention: Genetic Risk Score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Traditional Risk Factors
Number of subjects: 0
Study: 33981943

Group type: EXPERIMENTAL
Intervention: Bovine Milk Fat Globule Membrane and Lactoferrin in infant formula
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (cow-milk-based infant formula without MFGM and LF)
Number of subjects: 0
Study: 33981997

Group type: EXPERIMENTAL
Intervention: Gain-framed intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loss-framed intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 33982083

Group type: EXPERIMENTAL
Intervention: Perinatal depressive symptoms
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Adherence to antiretroviral therapy (ART)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Viral suppression (VS)
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Indirect effect of depressive symptoms on VS via ART adherence
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Direct effect of depressive symptoms on VS
Number of subjects: 1869

Group type: EXPERIMENTAL
Intervention: Overall effect of depressive symptoms on VS
Number of subjects: 1869
Study: 33982118

Group type: EXPERIMENTAL
Intervention: Serum Erythroferrone (ERFE)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO)
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Hepcidin-to-EPO ratio
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Maternal ERFE
Number of subjects: 297

Group type: EXPERIMENTAL
Intervention: Hepcidin-to-EPO ratio and EPO
Number of subjects: 297
Study: 33982128

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration ≤9.9 ng/mL
Number of subjects: 40

Group type: COMPARATOR
Intervention: Serum 25(OH)D concentration >9.9 ng/mL
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Serum 25(OH)D concentration
Number of subjects: 40
Study: 33982376

Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg, multiple oral doses on days 1-4)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vancomycin (500 mg, multiple oral doses on days 11-17)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Metformin + Vancomycin (1000 mg metformin on days 16-19)
Number of subjects: 9
Study: 33982592

Group type: EXPERIMENTAL
Intervention: Overlap syndrome (COPD and OSA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COPD only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OSA only
Number of subjects: 0

Group type: COMPARATOR
Intervention: Former smoker controls
Number of subjects: 0
Study: 33982599

Group type: EXPERIMENTAL
Intervention: hs-cTnT above upper reference limit
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: hs-cTnT quartiles comparison
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 562
Study: 33982909

Group type: EXPERIMENTAL
Intervention: Recipient body mass index at the time of liver biopsy
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Untreated hepatitis C viral (HCV) infection
Number of subjects: 183

Group type: COMPARATOR
Intervention: Donor steatosis
Number of subjects: 183

Group type: COMPARATOR
Intervention: Donor and recipient metabolic syndrome features
Number of subjects: 183

Group type: COMPARATOR
Intervention: Steatohepatitis
Number of subjects: 183
Study: 33983123

Group type: EXPERIMENTAL
Intervention: Apple Watch (minimum 12 hours/day) during RT
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Apple Watch
Number of subjects: 10
Study: 33983131

Group type: EXPERIMENTAL
Intervention: Reduce Sitting
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Increase Transitions
Number of subjects: 405

Group type: COMPARATOR
Intervention: Healthy Living (Control)
Number of subjects: 405
Study: 33983492

Group type: EXPERIMENTAL
Intervention: Pre-treatment tumour-associated lymphocytes (TILs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Stromal lymphocytes (SLs)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Neo-adjuvant treatment
Number of subjects: 66
Study: 33983498

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Kalinox®
Number of subjects: 200
Study: 33983671

Group type: EXPERIMENTAL
Intervention: DARC-positive ABMR
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DARC expression
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: DARC immunohistochemistry
Number of subjects: 82
Study: 33984029

Group type: EXPERIMENTAL
Intervention: Mild Cognitive Impairment (MCI) patients
Number of subjects: 66

Group type: COMPARATOR
Intervention: Healthy Older Volunteers (HOV)
Number of subjects: 66
Study: 33984031

Group type: EXPERIMENTAL
Intervention: Presence of perioperative respiratory event (PRE)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Presence of perioperative respiratory event (PRE) with unplanned admission
Number of subjects: 312

Group type: COMPARATOR
Intervention: Presence of perioperative respiratory event (PRE) vs non-PRE
Number of subjects: 312
Study: 33984519

Group type: EXPERIMENTAL
Intervention: Multimodal intervention to improve cancer surveillance and genetic counseling/testing access
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Literacy-focused genetic counseling approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care genetic counseling
Number of subjects: 0
Study: 33984539

Group type: EXPERIMENTAL
Intervention: Daily ambulatory activity (AA) monitoring using accelerometric data from an insertable cardiac monitor.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Baseline AA measurement.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Follow-up data for 45 participants with AA monitoring.
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: AA during the early subacute period.
Number of subjects: 186
Study: 33984672

Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg intravenously every 3 weeks
Number of subjects: 969
Study: 33984675

Group type: EXPERIMENTAL
Intervention: Intrathecal therapy (IT) with cytarabine or thiotepa
Number of subjects: 312

Group type: COMPARATOR
Intervention: Intrathecal therapy (IT) with methotrexate
Number of subjects: 312

Group type: COMPARATOR
Intervention: Concomitant systemic therapy
Number of subjects: 312

Group type: COMPARATOR
Intervention: Triple-negative subtype
Number of subjects: 312

Group type: COMPARATOR
Intervention: Treatment line ≥3
Number of subjects: 312

Group type: COMPARATOR
Intervention: ≥3 other metastatic sites
Number of subjects: 312

Group type: COMPARATOR
Intervention: Curie score and Breast-graded prognostic assessment
Number of subjects: 312
Study: 33984674

Group type: EXPERIMENTAL
Intervention: pN1mi (lymph node micro-metastases)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: pN1 (macro-metastases)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: pN1 = 1 (single macro-metastases)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: pN1 > 1 (multiple macro-metastases)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: pN1macro (in matched population analysis)
Number of subjects: 13773

Group type: EXPERIMENTAL
Intervention: pN1mi (in matched population analysis)
Number of subjects: 13773
Study: 33984846

Group type: EXPERIMENTAL
Intervention: Wireless measurements of vital signs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard measurements of vital signs
Number of subjects: 0
Study: 33985406

Group type: EXPERIMENTAL
Intervention: 6-minute pegboard and ring test (6PBRT)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 6PBRT
Number of subjects: 34
Study: 33985471

Group type: EXPERIMENTAL
Intervention: High maternal fruit and vegetable intake with baby lead weaning
Number of subjects: 144

Group type: COMPARATOR
Intervention: Standard maternal fruit and vegetable intake with spoon feeding
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Maternal diet and psychological features during pregnancy and breastfeeding
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Compositional and physicochemical analysis of milk during breastfeeding
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Children's diet during weaning until 18 months of age
Number of subjects: 144
Study: 33985574

Group type: EXPERIMENTAL
Intervention: Evidence-based informed consent forms for TKA and related anesthesia procedures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard consent forms
Number of subjects: 0
Study: 33985811

Group type: EXPERIMENTAL
Intervention: Neoadjuvant pembrolizumab (200 mg for 2 cycles before surgery)
Number of subjects: 35
Study: 33986031

Group type: EXPERIMENTAL
Intervention: Anticoagulation therapy (initial therapy)
Number of subjects: 7438

Group type: EXPERIMENTAL
Intervention: Computed tomographic pulmonary angiography (diagnostic approach)
Number of subjects: 7438

Group type: EXPERIMENTAL
Intervention: All-cause mortality
Number of subjects: 7438
Study: 33986044

Group type: EXPERIMENTAL
Intervention: Enhanced primary healthcare approaches including risk screening, patient engagement, shared decision making, and care coordination.
Number of subjects: 9
Study: 33986057

Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs), two doses with an intervention interval of 3 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard COPD medication treatment based on GOLD 2019 guidelines and Vietnam Ministry of Health protocol.
Number of subjects: 40
Study: 33986123

Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: anti-PD-1 resistant tumors
Number of subjects: 36
Study: 33986124

Group type: EXPERIMENTAL
Intervention: Ex vivo armed T cells (EATs) using IgG-[L]-scFv-platformed bispecific antibodies (BsAb)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ex vivo armed T cells (EATs) using γδ T cells
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate BsAb and T cell injection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EAT therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EATs after cryopreservation
Number of subjects: 0
Study: 33986214

Group type: EXPERIMENTAL
Intervention: Open fracture wounds
Number of subjects: 2500
Study: 33986719

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33986914

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) using low-cost VR goggles with a roller coaster application during the procedure
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard of Care (SOC) during the procedure
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 62
Study: 33987172

Group type: EXPERIMENTAL
Intervention: Low-Magnitude High-Frequency Vibration (LMHFV)
Number of subjects: 972

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 972
Study: 33987246

Group type: EXPERIMENTAL
Intervention: Successful Spontaneous Breathing Trial (SBT)
Number of subjects: 46
Study: 33987279

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH) at 33 °C for ≥72 h
Number of subjects: 192

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (TH)
Number of subjects: 192
Study: 33987718

Group type: EXPERIMENTAL
Intervention: Healthcare staff in COVID-19 units
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: All healthcare staff
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Non-healthcare staff
Number of subjects: 971

Group type: COMPARATOR
Intervention: COVID-19 ICU staff
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Contact with a COVID-19-confirmed household
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Working in a COVID-19 unit
Number of subjects: 971

Group type: EXPERIMENTAL
Intervention: Contact with a confirmed COVID-19 coworker
Number of subjects: 971

Group type: COMPARATOR
Intervention: Working in the COVID-19 ICU
Number of subjects: 971
Study: 33988272

Group type: EXPERIMENTAL
Intervention: Single-cell RNA sequencing of monocytes
Number of subjects: 0
Study: 33988508

Group type: EXPERIMENTAL
Intervention: Adaptive GameSquad (AGS) intervention
Number of subjects: 23

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 23
Study: 33988513

Group type: EXPERIMENTAL
Intervention: SMS and HBPM (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care and HBPM (n=12)
Number of subjects: 24
Study: 33988517

Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy (CBT)
Number of subjects: 350

Group type: COMPARATOR
Intervention: Education
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Digital CBT
Number of subjects: 350
Study: 33988847

Group type: EXPERIMENTAL
Intervention: Implementation strategies identified through Innovation Tournament (IT) with agency staff stakeholders.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Engagement strategies for parents and youth.
Number of subjects: 26
Study: 33988881

Group type: EXPERIMENTAL
Intervention: Vismodegib treatment
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Surgery post-Vismodegib treatment
Number of subjects: 34
Study: 33988944

Group type: EXPERIMENTAL
Intervention: Individualized variability- and chronobiology-based therapy for analgesics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotherapy based on circadian rhythm
Number of subjects: 0
Study: 33989296

Group type: COMPARATOR
Intervention: Brushing, dental floss, and tongue scraper
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, and aPDT
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, and probiotics
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Brushing, dental floss, aPDT, and probiotics
Number of subjects: 88
Study: 33989558

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (150 μg/kg for two cycles, then 75 μg/kg thereafter, intravenously on day 1 of each 21-day cycle)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine
Number of subjects: 145
Study: 33989764

Group type: EXPERIMENTAL
Intervention: Benzyl isothiocyanate (BITC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BITC in combination with other drugs
Number of subjects: 0
Study: 33990027

Group type: EXPERIMENTAL
Intervention: Increased presence of intervillous fibrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased placental syncytial knotting
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Standardized morphological study of post-date placentas
Number of subjects: 0
Study: 33990076

Group type: EXPERIMENTAL
Intervention: e-CBT program delivered through the Online Psychotherapy Tool, 12 weekly sessions tailored to MDD.
Number of subjects: 110

Group type: COMPARATOR
Intervention: In-person CBT, 12 weekly sessions.
Number of subjects: 110
Study: 33990084

Group type: EXPERIMENTAL
Intervention: iPlan Flow software for estimating infusate distribution
Number of subjects: 10
Study: 33990101

Group type: EXPERIMENTAL
Intervention: Stopping disease-modifying therapies (DMTs)
Number of subjects: 0
Study: 33990364

Group type: EXPERIMENTAL
Intervention: Domperidone
Number of subjects: 1190987

Group type: COMPARATOR
Intervention: Control (no domperidone)
Number of subjects: 1190987
Study: 33990413

Group type: EXPERIMENTAL
Intervention: Invasive revascularisation (186 patients, 85.7%)
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Invasive management
Number of subjects: 217
Study: 33990415

Group type: EXPERIMENTAL
Intervention: 120mg/kg cyclophosphamide and 125mg/m2 fludarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 60mg/kg cyclophosphamide and 125mg/m2 fludarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 30mg/kg cyclophosphamide and 75mg/m2 fludarabine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total body irradiation (TBI) and 75mg/m2 fludarabine
Number of subjects: 0
Study: 33990496

Group type: EXPERIMENTAL
Intervention: HIV-positive participants
Number of subjects: 358

Group type: COMPARATOR
Intervention: HIV-negative participants
Number of subjects: 358
Study: 33990507

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA), specifically atrasentan, in addition to blockade of the renin-angiotensin-aldosterone system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endothelin receptor antagonists (ERA)
Number of subjects: 0
Study: 33990512

Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 0

Group type: COMPARATOR
Intervention: PCSK9-blocking monoclonal antibodies
Number of subjects: 0
Study: 33990649

Group type: EXPERIMENTAL
Intervention: Combined model incorporating automated volumes of selected brain regions on MRI and SUVRs of Braak ROIs on [18F] THK-5351 PET
Number of subjects: 113

Group type: COMPARATOR
Intervention: SUVRs of Braak ROIs on [18F] THK-5351 PET
Number of subjects: 113
Study: 33990663

Group type: EXPERIMENTAL
Intervention: 23 mg donepezil sustained release
Number of subjects: 0

Group type: COMPARATOR
Intervention: 10 mg donepezil immediate release
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) arm
Number of subjects: 0
Study: 33991326

Group type: EXPERIMENTAL
Intervention: Apomorphine Sublingual Film (APL) at doses of 15/20/25/30 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous Apomorphine (SC-APO) at doses of 2/3/4/5 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subcutaneous Apomorphine-GO (SC-APO-GO) at doses of 2/3/4/5 mg
Number of subjects: 0
Study: 33991323

Group type: EXPERIMENTAL
Intervention: Bisoprolol/Perindopril single-pill combination (SPC)
Number of subjects: 1892
Study: 33991512

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin (1.25 mg/kg IV on days 1, 8, and 15 of every 28-day cycle)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Number of subjects: 89
Study: 33991553

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI)
Number of subjects: 41

Group type: COMPARATOR
Intervention: A-line Autoregression Index (AAI)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) before intubation
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) at 10 minutes intraoperatively
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Perfusion Index (PI) during recovery
Number of subjects: 41
Study: 33992295

Group type: EXPERIMENTAL
Intervention: Releasing quadratus lumborum muscle
Number of subjects: 30
Study: 33992550

Group type: EXPERIMENTAL
Intervention: TAVR with MR regression
Number of subjects: 7303

Group type: EXPERIMENTAL
Intervention: TAVR with MR persistence
Number of subjects: 7303

Group type: EXPERIMENTAL
Intervention: TAVR with nonsignificant baseline MR
Number of subjects: 7303

Group type: EXPERIMENTAL
Intervention: Staged mitral intervention after TAVR
Number of subjects: 7303

Group type: COMPARATOR
Intervention: No staged mitral intervention after TAVR
Number of subjects: 7303
Study: 33992564

Group type: EXPERIMENTAL
Intervention: N-terminal pro-B-type natriuretic peptide-guided titration of guideline-directed medical therapy (GDMT)
Number of subjects: 894

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 894
Study: 33992569

Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 0
Study: 33992606

Group type: EXPERIMENTAL
Intervention: Angio-iFR medical software device (Philips, San Diego, US)
Number of subjects: 440
Study: 33992635

Group type: EXPERIMENTAL
Intervention: MSICare
Number of subjects: 333

Group type: COMPARATOR
Intervention: MSISensor
Number of subjects: 333
Study: 33993135

Group type: EXPERIMENTAL
Intervention: Psychedelic-assisted therapy
Number of subjects: 0
Study: 33993383

Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) 100 mg/m² combined with weekly irinotecan (20 mg twice per day on days 1-3 and 8-10)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Alisertib (MLN8237) combined with weekly irinotecan
Number of subjects: 17
Study: 33993651

Group type: EXPERIMENTAL
Intervention: Liver fibrosis assessment
Number of subjects: 0
Study: 33993741

Group type: EXPERIMENTAL
Intervention: Regorafenib with trifluridine/tipiracil (TAS-102) combination treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil at 25 mg/m2
Number of subjects: 0
Study: 33993815

Group type: EXPERIMENTAL
Intervention: Glasdegib (100 mg QD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glasdegib (supratherapeutic concentrations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glasdegib (5-640 mg QD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 33993853

Group type: EXPERIMENTAL
Intervention: Fucoxanthin, specific dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other carotenoids, specific details not available
Number of subjects: 0
Study: 33994087

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33994151

Group type: EXPERIMENTAL
Intervention: Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB)
Number of subjects: 37
Study: 33994208

Group type: EXPERIMENTAL
Intervention: Ministernotomy
Number of subjects: 986

Group type: COMPARATOR
Intervention: Minithoracotomy
Number of subjects: 986
Study: 33994338

Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (Life's simple 7 score categorized in tertiles: poor, intermediate, ideal)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (specifically in men)
Number of subjects: 886

Group type: EXPERIMENTAL
Intervention: Higher ideal cardiovascular health (not specified for women)
Number of subjects: 886
Study: 33995015

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) up to 800 mg/day for 4 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Amisulpride (AMI) up to 800 mg/day for 4 weeks
Number of subjects: 42
Study: 33995239

Group type: EXPERIMENTAL
Intervention: Epigallocatechin Gallate, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33995257

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 33995588

Group type: EXPERIMENTAL
Intervention: Matched targeted therapy based on ctDNA analysis and/or tumor molecular profiling
Number of subjects: 3
Study: 33995600

Group type: EXPERIMENTAL
Intervention: Apatinib 500 mg once daily
Number of subjects: 68
Study: 33995597

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 152